The selective depletion of immunosuppressive Tregs aligns with preclinical studies demonstrating that OX40 agonists can deplete intratumoral Tregs via FcγR-mediated mechanisms, thereby enhancing anti-tumor immunity (33). Here, TNFRSF4 is linked to neoplasm.